未登录

D

David Heimbrook

roche holding

H指数:41

被引数:6,567

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Small-molecule inducer of cancer cell polyploidy promotes apoptosis or senescence Implications for therapy

IF3.4

2014-10-3128

OAAI

Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation

IF3.4

2014-10-2775

PREAI

Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach

CLINICAL CANCER RESEARCH

IF10.2

2014-07-1467

OAAI

Discovery of siRNA Lipid Nanoparticles to Transfect Suspension Leukemia Cells and Provide In Vivo Delivery Capability

MOLECULAR THERAPY

IF12

2014-02-0164

OAAI

Humanized hepsin neutralizing antibody RO5486055 inhibits tumor growth and leads to accumulation of hepsin substrate laminin-332

CANCER RESEARCH

IF16.6

2012-04-010

PRE

Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation

CANCER RESEARCH

IF16.6

2012-02-14160

OAAI

Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer

CANCER RESEARCH

IF16.6

2012-01-31208

OAAI

Identification of the MEK1(F129L) Activating Mutation as a Potential Mechanism of Acquired Resistance to MEK Inhibition in Human Cancers Carrying the B-Raf V600E Mutation

CANCER RESEARCH

IF16.6

2011-08-1170

OAAI

MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer

MOLECULAR CANCER

IF33.9

2011-05-0341

OAAI

Activating MEK1(F129L) mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation

CANCER RESEARCH

IF16.6

2011-04-010

PRE

Efficacy of RG7204 (PLX4032), a selective BRAFV600E inhibitor, in combination with pegylated interferon alpha-2a (Pegasys), paclitaxel, carboplatin, and anti-VEGF MAb B20-4.1 in the LOX-IMVI human melanoma xenograft model

CANCER RESEARCH

IF16.6

2011-04-010

PRE

High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the γ-secretase inhibitor, RO4929097

MOLECULAR ONCOLOGY

IF4.5

2011-01-2144

OA

RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models

CANCER RESEARCH

IF16.6

2010-06-30415

OAAI

Preclinical In vivo Evaluation of Efficacy, Pharmacokinetics, and Pharmacodynamics of a Novel MEK1/2 Kinase Inhibitor RO5068760 in Multiple Tumor Models

MOLECULAR CANCER THERAPEUTICS

IF5.5

2010-01-1229

OAAI

Preclinical Profile of a Potent γ-Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic Properties

CANCER RESEARCH

IF16.6

2009-10-01189

OAAI

Characterization of a Novel Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor with a Unique Mechanism of Action for Cancer Therapy

CANCER RESEARCH

IF16.6

2009-03-0236

OAAI

In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models

MOLECULAR CANCER THERAPEUTICS

IF5.5

2009-01-1239

PREAI

A selective phosphatase of regenerating liver phosphatase inhibitor suppresses tumor cell anchorage-independent growth by a novel mechanism involving p130Cas cleavage

CANCER RESEARCH

IF16.6

2008-02-1589

OAAI

In vitro and in vivo activity of R547:: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials

MOLECULAR CANCER THERAPEUTICS

IF5.5

2006-11-22118

OAAI

Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IF9.1

2006-07-11687

OAAI